Not all chip stocks enjoyed the exuberant first-half performance seen by Nvidia — and a Melius Research analyst thinks some ...

The May 30 jump in Momentus’s stock was driven by the announcement of a contract with the Defense Advanced Research Projects ...

“According to the naysayers, earnings growth expectations are too high because there are mounting signs of an economic ...

The company, which makes glass for big-screen TVs, mobile phones and optical fiber, believes the first quarter will be the ...

This does not mean the economy doesn’t matter to the stock market. But their relationship is too complex and inscrutable to ...

Shares of HilleVax plummeted after the company said it would end development on its norovirus vaccine for infants given disappointing results from a recent trial.

Ligand Pharmaceuticals has agreed to buy private biopharmaceutical company Apeiron Biologics for $100 million in cash in a deal that adds royalty rights to the cancer drug Qarziba to its ...

Volue shares rose after the company said it received a 6.04 billion Norwegian Krone ($573.1 million) takeover approach from a company backed by its largest shareholder, but advised shareholders not to ...

HilleVax is ending development on its norovirus vaccine for infants after its latest trial of the shot missed its primary and secondary efficacy endpoints.

A Russian missile attack hit a children’s hospital in Ukraine’s capital. Ukrainian officials said Russia targeted multiple cities, leaving at least 20 people dead and dozens wounded. Photo: Evgeniy ...

Oppenheimer's John Stoltzfus, chief investment strategist in the company's asset-management business, has just raised his year-end S&P 500 target for the second time this year. Stoltzfus expects the ...

Regeneron Pharmaceuticals expects to incur an acquired in-process research and development charge of about $24 million in the second quarter, which should negatively impact earnings per share.